Recipient Hyperbilirubinemia May Reduce Ischemia-Reperfusion Injury but Fails to Improve Outcome in Clinical Liver Transplantation
Authors
Oltean, MihaiBarrenas, Christian
Martins, Paulo N.A.
Herlenius, Gustaf
Gustafsson, Bengt
Friman, Styrbjorn
Bennet, William
UMass Chan Affiliations
Department of Surgery, Transplant DivisionDocument Type
Journal ArticlePublication Date
2016-05-22Keywords
liver transplantationbilirubin
hyperbilirubinemia
schemia-reperfusion injury
Biological Factors
Clinical Epidemiology
Epidemiology
Gastroenterology
Hepatology
Pathological Conditions, Signs and Symptoms
Surgery
Surgical Procedures, Operative
Metadata
Show full item recordAbstract
Background. Exogenous bilirubin may reduce experimental ischemia-reperfusion injury (IRI) due to its antioxidant properties. We studied if early graft exposure to high bilirubin levels in the recipient affects the early IRI and outcomes after liver transplantation (LTx). Methods. In 427 LTx patients, the AUROC curve based on bilirubin and AST at day 1 identified a cutoff of 2.04 mg/dL for the recipient pretransplant bilirubin. Recipients were grouped as having low (group L, n = 152) or high (group H, n = 275) bilirubin. Both groups had similar donor-related variables (age, preservation time, donor BMI > 28, and donor risk index (DRI)). Results. Alanine (ALT) and aspartate (AST) aminotransferase levels were higher in group L at day 1; ALT levels remained higher at day 2 in group L. LTx from high risk donors (DRI > 2) revealed a trend towards lower transaminases during the first two days after transplantation in group H. One month and 1-year patient survival were similar in groups L and H. High preoperative bilirubin did not affect the risk for early graft dysfunction (EGD), death, or graft loss during the first year after transplantation nor the incidence of acute rejection. LTx using donors with DRI > 2 resulted in similar rates of EGD in both groups. Conclusion. Increased bilirubin appears to reduce the early IRI after LTx yet this improvement was insufficient to improve the clinical outcome.Source
Gastroenterol Res Pract. 2016;2016:6964856. doi: 10.1155/2016/6964856. Epub 2016 May 22. Link to article on publisher's site
DOI
10.1155/2016/6964856Permanent Link to this Item
http://hdl.handle.net/20.500.14038/49749PubMed ID
27313607Related Resources
Rights
Copyright © 2016 Mihai Oltean et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Distribution License
http://creativecommons.org/licenses/by/4.0/ae974a485f413a2113503eed53cd6c53
10.1155/2016/6964856
Scopus Count
Collections
Except where otherwise noted, this item's license is described as Copyright © 2016 Mihai Oltean et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.